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Considerable evidence has been gathered over the last 10 years showing that the tumor
microenvironment (TME) is not simply a passive recipient of immune cells, but an active
participant in the establishment of immunosuppressive conditions. It is now well docu-
mented that hypoxia, within the TME, affects the functions of immune effectors including
natural killer (NK) cells by multiple overlapping mechanisms. Indeed, each cell in the TME,
irrespective of its transformation status, has the capacity to adapt to the hostile TME and
produce immune modulatory signals or mediators affecting the function of immune cells
either directly or through the stimulation of other cells present in the tumor site. This
observation has led to intense research efforts focused mainly on tumor-derived factors.
Notably, it has become increasingly clear that tumor cells secrete a number of environ-
mental factors such as cytokines, growth factors, exosomes, and microRNAs impacting
the immune cell response. Moreover, tumor cells in hostile microenvironments may acti-
vate their own intrinsic resistance mechanisms, such as autophagy, to escape the effective
immune response. Such adaptive mechanisms may also include the ability of tumor cells to
modify their metabolism and release several metabolites to impair the function of immune
cells. In this review, we summarize the different mechanisms involved in the TME that
affect the anti-tumor immune function of NK cells.
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INTRODUCTION
Natural killer (NK) cells are potent cytolytic lymphocytes belong-
ing to the innate immune system. NK cells comprise up to 15% of
all circulating lymphocytes and are also found in peripheral tissues
including the liver, peritoneal cavity, and the placenta. Although
resting NK cells circulate in the blood, they are capable of infiltrat-
ing most cancer tissues following activation by cytokines. NK cells
can be rapidly activated in the periphery by NK cell stimulatory
factors, such as interleukin (IL)-12, interferon (IFN)-α and -β, IL-
15, or IL-2 (1). Regulation of NK cell activity depends on the reper-
toire of germline-encoded activating and inhibitory receptors. The
activating receptors recognize stress-induced, pathogen-derived,
or tumor-specific ligands, whereas the inhibitory receptors bind
self-molecules presented on normal cells. Owing to a diversified
set of inhibitory and activating receptors, NK cells are capable of
recognizing and killing an array of tumor cells (2). Beyond innate
activity, NK cells are important for the regulation of anti-tumor
adaptive immunity (3, 4).
In addition to their well-described role in inhibiting the early
stage of tumor formation, NK cells are able to eradicate large solid
tumors. Such eradication depends on the massive infiltration of
proliferating NK cells due to the release and the presentation of
IL-15 by cancer cells in the tumor microenvironment (TME). It
has been shown that infiltrating NK cells are strikingly similar
morphologically to uterine NK cells (5).
Based on the fact that NK cells can eliminate cancer cells in
experimental conditions, it has been proposed that NK cells can be
used clinically in therapeutic settings against cancer. Importantly,
data from haploidentical hematopoietic stem cell transplantation
and NK cell-based adoptive immunotherapy support the clini-
cal effects of NK cells (6). Based on our current knowledge of
the molecular specificities that regulate NK cell functions, it is
tempting to speculate that a design of tailored NK cell-based
immunotherapeutic strategies against cancer might be possible.
Recent data confirm that NK cells are required for the induc-
tion of potent anti-tumor-specific cytotoxic T lymphocytes (T
cells) responses, by a mechanism involving dendritic cell (DC)
editing (7, 8). Furthermore, NK cells can recognize tumors that
might evade T cell-mediated killing by aberrant human leukocyte
antigen (HLA) expression (9), indicating that NK cells participate
in tumor immunosurveillance.
A significant correlation between high intratumoral levels of
NK cells and increased survival has been shown in several types
of cancer (10). Indeed, high levels of NK-infiltrating tumors
have been associated with a significant improvement of clinical
outcomes in patients with head and neck squamous carcinoma
(HNSCC). It has been reported by van Herpen et al. that CD56+
NK cells in lymph nodes produced considerable amounts of IFN-
γ that subsequently lead to tumor regression in IL-12-treated
HNSCC patients (11). A direct positive correlation between the
density of CD57+NK cells and a good prognosis has been reported
for oral squamous carcinoma (12) and gastric carcinoma (GC)
tumors (13). In addition, NK cell infiltration was found to also
correlate with the depth of invasion, the clinical stage, and the
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venous invasion. Therefore, the 5-year survival rate of GC patients
with a high rate of NK infiltration was significantly better than
that of patients with a low level of NK infiltration (13).
Natural killer-based immunotherapy is a promising strategy
for solid and hematologic cancers and it can potentially be
combined with chemotherapy, radiation, or monoclonal anti-
body therapy. For example, the proteasome inhibitor bortezomib
(Velcade®), which is clinically approved for the treatment of
refractory/relapsed myeloma, downregulates the expression of
major histocompatibility complex (MHC) class I on the tar-
get cell surface and thereby shifts the balance toward NK cell
activation and target cell killing (14). Therefore, such combi-
nation therapy has important therapeutic implications for mul-
tiple myeloma (MM) and NK cell-related malignancies in the
context of adoptively transferred allogeneic and autologous NK
cells (15). NK cell-based therapy can be combined with radi-
ation therapy as irradiation-induced tissue injury increases the
expression of NK-activating ligands (e.g., NKG2D ligands) on
malignant cells, thereby rendering tumors more susceptible to
NK cell cytotoxic activity (16) Another NK cell-based approach
used in therapy is the antibody-dependent cellular cytotoxicity
(ADCC). This approach is based on the ability of NK cells, express-
ing an activating Fc receptor, to kill tumor cells by recognizing the
constant region of tumor-bound monoclonal antibodies (mAbs).
Clinically, ADCC strategy has been used in CD20+ lymphoma
patients treated with rituximab (Rituxan™) (17) or HER2/neu-
expressing breast cancer patients treated with trastuzumab (Her-
ceptin™) (18). It is important to note that the co-administration
of immunomodulatory cytokines (e.g., IL-12) can enhance the
effects of anti-tumor mAbs via the activation of NK cells in vitro.
This effect has been observed in breast cancer patients overex-
pressing HER2/neu and treated with IL-12 and trastuzumab in a
phase I trial (19).
Despite the progress made in the field of NK-based
immunotherapy, there are still many obstacles to eliciting an effec-
tive immune response. One major impediment is the ability of
tumor cells to activate several mechanisms that lead to tumor
escape from NK-mediated killing. It has become increasingly
clear that the TME plays a crucial role in the impairment of the
immune response and in the development of many overlapping
mechanisms that create an immunosuppressive microenviron-
ment. It has been reported that tumor-associated NK cells display
a modified phenotype, thereby supporting the notion that tumor-
induced alterations of activating NK cell receptor expression may
hamper immune surveillance and promote tumor progression
(20). Decreased cytotoxic activity of NK cells infiltrating tumors
was also observed in different types of human cancer such as
lung carcinoma (21), indicating that the TME is a critical fac-
tor influencing NK-mediated killing of tumor cells. Hypoxia, a
characteristic feature of advanced solid tumors resulting from
defective vascularization and a subsequent insufficient oxygen
supply, is considered one of the hallmarks of the TME (22). It
is now well established that hypoxia contributes to malignant
progression in cancer by inducing an invasive and metastatic phe-
notype of tumor cells and by activating resistance mechanisms to
different anti-cancer therapies (23). Extensive efforts have been
made in recent years to identify these mechanisms. We review
here how the local microenvironment, in the particular con-
text of hypoxia, impacts NK cell responsiveness and shapes the
anti-tumor response (Figure 1).
TUMOR-DERIVED FACTORS CREATE AN
IMMUNOSUPPRESSIVE MICROENVIRONMENT FOR NK CELL
FUNCTIONS
IMPAIRMENT OF NK CELL FUNCTION BY CELLS FROM THE TUMOR
MICROENVIRONMENT
Hypoxic tumor cells have the ability to activate resistance
mechanisms to create an immunosuppressive microenvironment.
Indeed, through their ability to produce cytokines such as tumor
necrosis factor (TNF)-α and stromal cell-derived factor 1 (SDF-1),
hypoxic tumor cells induce the homing of bone marrow-derived
CD45+myeloid cells to tumor areas (24). The invasion of myeloid
cells in the TME is reported to be a highly immunosuppres-
sive factor for NK cells (25). Myeloid-derived suppressor cells
(MDSCs) are one of the major components of the immune-
suppressive network responsible for the impairment of NK cell-
and T cell-dependent anti-cancer immunity (26). The immuno-
suppressive function of MDSCs is related to their production of
IL-10 that decreases the production by macrophages of IL-12,
a pro-inflammatory cytokine involved in the activation of NK
cells (27). It has also been shown that cancer-expanded MDSCs
induce anergy of NK cells by inhibiting cytotoxicity, NKG2D
expression, and IFN-γ production through membrane-bound
transforming growth factor (TGF)-β (28). Furthermore, it has
been demonstrated that hypoxia, via the induction of hypoxia-
inducible factor (HIF) 1-α in MDSCs, is responsible for their
differentiation to tumor-associated macrophages (TAMs) (29).
Although macrophages contribute to tumor cell death in the early
immune response to neoplasia, their presence in the TME corre-
lates with a poor prognosis for patients with advanced stages of
cancer (30, 31).
Macrophages constitute another major myeloid component of
the infiltrated tumors and can comprise up to 80% of the cell
mass in breast carcinoma (32). Hypoxic tumor secrete chemoat-
tractants [e.g., colony-stimulating factor (CSF)-1, CC chemokine
ligands (CCL) 2 and 5], resulting in the recruitment of mono-
cytes from the blood to the tumor site. Infiltrated monocytes
differentiate into CD206+ TAMs and accumulate in hypoxic areas
of endometrial, breast, prostate, and ovarian cancers (30). This
process is driven by tumor-secreted molecules such as endothe-
lial monocyte-activating polypeptide (EMAP) II, endothelin 2,
and vascular endothelial growth factor (VEGF) and also by the
inhibition of the CC chemokine receptors (CCRs) 5 and 2 expres-
sion (33). Exposure of TAMs to tumor-derived cytokines such
as IL-4 and IL-10 converts the TAMs into polarized type II
or M2 macrophages owing to the immunosuppressive and pro-
angiogenic activities. Subsequently, M2 macrophages establish an
environment that skews CD4+ and CD8+T cell immunity toward
a tumor-promoting type 2 response (34). It has been also demon-
strated that hypoxia upregulates the expression of the matrix
metalloproteinase (MMP)-7 protein on the TAM surface, lead-
ing to the cleavage of Fas ligand from neighboring cancer cells,
making them less responsive to NK cells and T cell-mediated lysis
(35) (Figure 2).
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FIGURE 1 |The tumor microenvironment activates different
mechanisms to impair the NK-mediated anti-tumor immunity. Under
the pressure of the tumor microenvironment (TME), tumor cells adapt to
such stress by activating intrinsic resistance mechanisms (autophagy) or by
regulating their metabolism. Such regulation leads to the secretion of
several metabolites that impair the function of NK cells in the tumor site
(yellow area). Tumor cells under stress conditions may activate the release
of tumor-derived vesicles containing cytokines, growth factors, or
microRNAs to directly impact the NK functions (blue area). Such factors
can be secreted directly in the TME to recruit immunosuppressive cells or
to educate stromal cells involved in the impairment of NK cell functions
(green area).
Recently, a link between tumor hypoxia and immune tolerance
to NK cells through the recruitment of regulatory T (Treg) cells
has been established. Hypoxia induces secretion of the immuno-
suppressive cytokine TGF-β from gastric cancer cells, which sub-
sequently induces the proliferation and the accumulation of Treg
cells in the TME (36). Moreover, human Treg cells induce anergy
of NK cells through membrane-bound TGF-β and subsequently
downregulate the activating receptor NKG2D on the surface of NK
cells (37).
The immunosuppressive microenvironment can also be cre-
ated through the ability of cancer cells to activate cancer-associated
fibroblasts (CAFs) via the release of TGF-β or IL-6 (38, 39). CAFs
have been shown to sharply interfere with NK cells cytotoxicity
and cytokine production. Notably, it has been reported that CAFs
are able to inhibit the IL-2-induced upregulation of the activat-
ing receptors NKp44, NKp30, and DNAX accessory molecule-1
(DNAM-1) at the NK cell surface. NKp44 and NKp30 expression is
modulated by prostaglandin E2 (PGE2) released from CAFs, while
DNAM-1 regulation requires cell-to-cell interaction. Such inhibi-
tion results in impaired NK cell-mediated killing of melanoma
target cells (40). Likewise, CAFs directly impact cells of the TME
and/or attract additional cells to the tumor site by secreting numer-
ous factors including IL-6, TGF-β, VEGF, SDF-1, CXCL1/2, and
IL-1β (41) (Figure 2).
Other mechanisms implicated in the establishment of immune-
suppressive microenvironment are the expression of the immune
checkpoint receptors, cytotoxic T-lymphocyte antigen (CTLA)-
4, and the programed death receptor (PD)-1. Such receptors
appear to play important roles in anti-tumor immunity and
have been most actively studied in the context of clinical cancer
immunotherapy. However, the effect of the TME on their reg-
ulation is poorly investigated. Nevertheless, the TME has been
shown to mediate the induction of the PD-1 pathway (42). In
line with this observation, NK cells from MM patients express
PD-1, whereas normal NK cells do not. Anti-PD-1 antibody-
based therapy enhances human NK cell function against autol-
ogous primary MM cells (43), highlighting the role of the PD-
1/PD-L1 signaling axis in NK-mediated immune response against
tumors. There is no direct evidence so far linking hypoxia and
the induction of CTLA-4 expression and the PD-1/PD-L1 path-
way. Further investigations are required to determine the pre-
cise role of the TME in the regulation of CTLA-4 and the
PD-1/PD-L1 pathways.
INHIBITION OF NK CELLS BY TUMOR CELL-DERIVED FACTORS
The MHC class I chain-related (MIC) molecules, MICA and
MICB, as well as the UL16-binding proteins (ULBPs), expressed
on the surface of a broad range of carcinomas and some
www.frontiersin.org December 2013 | Volume 4 | Article 490 | 3
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Baginska et al. Tumor microenvironment shapes NK functions
FIGURE 2 | Complex cellular interplay within the hypoxic tumor
microenvironment inhibits NK-mediated killing. Tumor cells in a hypoxic
tumor microenvironment (TME) secrete soluble factors that educate immune
cells [e.g., monocytes, tumor-associated macrophages (TAMs),
myeloid-derived suppressor cells (MDSCs), and regulatory T cells (Treg)], and
stromal cells such as cancer-associated fibroblasts (CAFs). This scheme
summarizes the effects of tumor-derived soluble factors on recruitment,
differentiation, proliferation, and activation of tumor-associated cells (red
arrows) in the hypoxic TME and their immunosuppressive activities (green
lines) on NK-mediated lysis of tumor cells.
hematopoietic malignancies, play an important role in tumor
surveillance by NK cells. The interaction of cell surface MIC mol-
ecules with NKG2D receptors on NK cells is critical to activate
target cell killing. In this context, hypoxia has been reported to
increase MICA shedding from the surface of cancer cells through
the impairment of nitric oxide (NO) signaling and therefore
affect the NK-mediated killing of target cells. Soluble MIC leads
to a downregulated expression of NKG2D and CXC chemokine
receptor (CXCR) 1 on the NK cell surface (44). This mecha-
nism involves the HIF-1α-dependent upregulation of A disintegrin
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and metalloproteinase domain-containing protein (ADAM) 10,
which subsequently decreases the level of MICA on the tumor cell
membrane (44, 45) (Figure 3).
In addition, hypoxic stress can induce the formation of dimers
of the non-classical MHC class I molecule HLA-G at the surface of
melanoma cells, thereby protecting tumor cells from NK-mediated
killing. It appears that such induction is mediated by secretion
of IFN-β and -γ and by direct interaction of HLA-G with NK
cells (46).
Inhibiting the expression of activating NK cell receptors,
including NKp30, NKp44, and NKG2D, has been shown to impair
NK cell-mediated cytolytic activity in a model of melanoma (47).
Although NK cells in the TME adapt and survive hypoxic stress by
upregulating HIF-1α, they lose the ability to upregulate the surface
expression of NKp46, NKp30, NKp44, and NKG2D receptors in
response to IL-2 or other activating cytokines (e.g., IL-15, IL-12,
and IL-21). However, it is important to note that hypoxia does not
significantly alter the surface density and the function of the Fc-γ
receptor CD16, thus allowing NK cells to maintain their capability
of killing target cells via ADCC (48).
In addition to solid tumors, the immunosuppressive effect
of the hypoxic TME has been also described in MM cells as
hypoxia reduced NK cell killing of MM cell lines despite an
unchanged NK cell degranulation level. In addition, hypoxia
did not alter the surface expression of NK cell ligands (HLA-
ABC and -E, MICA/B, and ULBP1-2) and receptors [killer cell
Ig-like receptors (KIR), NKG2A/C, DNAM-1, natural cytotox-
icity receptors (NCR), and 2B4], but decreased the expression
of the activating NKG2D receptor and intracellular level of
perforin and granzyme B. Pre-activation of NK cells by IL-2
removed the detrimental effects of hypoxia and increased NKG2D
expression (49).
It is now well documented that the killing capacity of NK cells
can be potentiated by cytokines such as IFN-γ and IL-2 (50, 51).
Besides its effect of damping the cytotoxic activity of NK cells,
hypoxia substantially decreases the ability of NK cells to be acti-
vated by IFN-γ through a mechanism that is not fully understood
(52). Overall, it appears that manipulation of the TME will be
an important consideration in achieving optimal NK-mediated,
anti-tumor responses.
Since NKG2D ligand mRNAs are expressed in normal tissues,
it has been proposed that their expression might be regulated
at the post-transcriptional level by microRNAs (miRNAs) (53).
Indeed, a subset of endogenous cellular miRNAs is proposed to
repress MICA and MICB by targeting their 3′ UTR regions (54).
Upon stress induction, the increase in MICA and MICB tran-
scription might exceed the inhibitory function of miRNAs, whose
expression remains constant, and result in an overexpression of
MICA and MICB. Interestingly, among this subset of miRNAs,
miR-17-5p, miR-20a, miR-93, miR-106b, miR-372, miR-373, and
miR-520 have been shown to be overexpressed in various tumors
and be involved in tumor progression and invasion. Therefore, a
new function of these miRNAs has been proposed in the impair-
ment of the immune response through the regulation of MICA
and MICB expression (Figure 1). Based on these observations, a
“miRNA-based immunoevasion” model has been described that
highlights intracellular cancer-associated miRNAs as important
factors able to impair immune recognition through the targeting
of NK ligands (54). Furthermore, miR-10b, an important “metas-
tamir,” has been described to downregulate MICB and decrease
the NKG2D-dependent cytotoxicity of NK cells (55). MiR-520b,
an IFN-γ-induced miRNA, has been described to regulate MICA
expression at both the transcriptional and post-transcriptional
levels (56). It has also been proposed that viruses can take advan-
tage of miRNA-based immunoevasion. Indeed, the hcmv-miR-
UL112 encoded by the human cytomegalovirus impairs NK cell
function during viral infection through the modulation of MICB
expression (57). In addition, hcmv-miR-UL112 acts synergistically
with the cellular miR-376a to induce escape from NK-mediated
immune elimination (58). Together, these studies highlight the
importance of miRNAs in the regulation of NKG2D ligand expres-
sion and tumor immune surveillance. Whether the expression of
such miRNAs is regulated by hypoxia in the TME remains to be
investigated.
TUMOR MICROENVIRONMENT-DEPENDENT MODULATION
OF CANCER CELL METABOLISM AFFECTS NK CELL
FUNCTIONS
Through the sensing of oxygen level and/or the transcriptional
activity of HIF-1α, hypoxia plays a key role in the reprograming
of cancer cell metabolism. Indeed, reduced O2 availability induces
HIF-1α, which regulates the transcription of a set of genes that
encode proteins involved in various aspects of cancer biology (59).
A well-known example is the shift of glucose and energy metab-
olism from oxidative to glycolytic metabolism that allows for the
maintenance of redox homeostasis under conditions of prolonged
FIGURE 3 | Soluble MICA/B regulate NKG2D receptors on the surface of
NK cells. Under hypoxic stress, tumor cells activate expression through
HIF-1α and the release of ADAM10. Released ADAM10 cleaves MICA/B
ligands on the surface of tumor cells and soluble MICA/B downregulates the
expression of NKG2D on the surface of NK cells, leading to tumor escape
from NK-mediated killing.
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hypoxia (60). The effects of such metabolic adaptations evolved
by hypoxic cancer cells have received particular attention in the
establishment of immune tolerance. In this section, we will focus
on the mechanisms involved in tumor metabolism adaptation that
participate in shaping the NK cell anti-tumor response within a
hypoxic microenvironment (Figure 1).
LACTATE
To adapt to oxygen deprivation, hypoxic cancer cells undergo a
dramatic alteration of cellular glucose metabolism characterized
by a high glycolytic activity. HIF-1α plays a central role in this
metabolic switch by inducing the expression of multiple genes
involved in glucose uptake (glucose transporters-1 and -3) and
metabolism (i.e., hexokinases-1 and -2 and lactate dehydrogenase
A) (61). In addition, HIF-1α regulates the expression of mono-
carboxylate transporter 4 and pyruvate dehydrogenase kinase 1,
thereby inhibiting the conversion of pyruvate to acetyl CoA (62).
The accumulation of pyruvate in cells prevents its metabolism
through the tricarboxylic acid cycle in mitochondria. Pyruvate
is subsequently reduced to lactate and finally released from the
tumor cells. It has been recently reported that cancer cells escape
immune response through the release of lactate in the microen-
vironment and the presence of a low extracellular pH, as a con-
sequence of the “Warburg effect” induced under hypoxia. In vivo
and in vitro evidence has been provided indicating that tumor-
derived lactate directly and indirectly alters NK cell functions.
The direct effect involves the impairment of the cytolytic activity
of NK cells by downregulating NKp46 expression and reduc-
ing perforin/granzyme B production. Moreover, lactate affects
the NK-mediated killing indirectly through the increased MDSCs
generation from mouse bone marrow, thus creating an immuno-
suppressive microenvironment. Interestingly, these immunosup-
pressive effects were efficiently reverted in a lactate dehydrogenase
A-depleted cancer model (63).
ADENOSINE
Hypoxia-driven accumulation of adenosine in the TME has been
identified as another mechanism for immune modulation (64). It
has been reported that the concentration of adenosine in the extra-
cellular fluid of solid carcinomas may be increased up to 20-fold
compared with normal tissues (65). The accumulation of adeno-
sine is sustained, at least in part, by the hypoxia-mediated modula-
tion of enzymes implicated in adenosine metabolism (i.e., adeno-
sine kinase, endo-5′-nucleotidase). Moreover, the additional gen-
eration of extracellular adenosine from extracellular ATP occurs
through the sequential enzymatic activity of the membrane-bound
nucleotidases CD39 and CD73. It has been shown that CD73,
involved in the dephosphorylation of AMP to adenosine, is upreg-
ulated by HIF-1α (66, 67). Once released in the extracellular envi-
ronment, adenosine exerts various immunomodulatory effects
via binding on adenosine receptors (i.e., A1, A2A, A2B, and A3)
expressed on multiple immune subsets including NK cells.
In contrast to other immune cells such as macrophages and
neutrophils, the effect of extracellular adenosine on NK cells is not
fully known. Adenosine has been shown to inhibit TNF-α release
from IL-2-stimulated NK cells and suppress their proliferation
(68). Another study reported that adenosine inhibits cytotoxic
granules exocytosis from murine NK cells via binding to an
unidentified adenosine receptor (69). More recently, data support
the fact that adenosine and its stable analog 2-chloroadenosine
inhibit perforin- and Fas ligand-mediated cytotoxic activity as
well as cytokines production (i.e., IFN-γ, macrophage inflam-
matory protein 1-α, TNF-α, and granulocyte-macrophage CSF)
from activated NK cells. These inhibitory effects occur through
the stimulation of the cyclic AMP/protein kinase A pathway fol-
lowing the binding of adenosine to A2A receptors on NK cells (70,
71). In this context, targeting the CD73-adenosine pathway has
recently emerged as a potential clinical strategy for immunother-
apy (66). In vitro data revealed that the inhibition of the CD39,
CD73, or A2A adenosine receptor by siRNA, shRNA, or specific
inhibitors resulted in a significant improvement of NK cell lytic
activity against ovarian cancer cells (72). Furthermore, in vivo
blocking of the A2A adenosine receptor enhanced NK cell activ-
ity in a perforin-dependent manner and reduced metastasis of
CD73-overexpressing breast cancer cells (73).
As multiple immune competent cells express adenosine recep-
tors, an additional level of immunomodulatory activity, via adeno-
sine, needs to be considered. For example, several studies reported
that adenosine interaction with other immune subsets impairs
the cytotoxic activity, the pro-inflammatory cytokines production,
and the proliferation of T cells. In addition, adenosine impairs the
recruitment and the immunosuppressive activity of MDSCs in
tumors, as well as the migration and the immunosuppressive func-
tion of Treg cells into the TME (74). Taken together, by sustaining
the immunoregulatory activity of extracellular adenosine, all the
mechanisms described above collaborate to impair the anti-tumor
NK-mediated immunity.
NITRIC OXIDE
Accumulating evidence suggests that the exposure of cells to low
oxygen levels results in a marked inhibition of NO production
(75). NO is produced from l-arginine in a reaction catalyzed by
the NO synthase (NOS) enzymes, in which oxygen is a required
cofactor. Hypoxia has also been shown to increase arginase activ-
ity, thereby redirecting l-arginine into the urea cycle, away from
the NO generation pathway (76). Siemens et al. provided evidence
that hypoxia-mediated impairment of NO signaling in tumor cells
contributes to tumor escape from NK immunosurveillance. They
demonstrated that hypoxia-mediated shedding of MIC occurs
through a mechanism involving impaired NO signaling in human
prostate cancer. Such shedding can be blocked after reactivating
NO signaling by the administration of NO mimetic agents (45).
This work suggests that reactivation of NO could help to overcome
hypoxia-driven tumor escape.
PROSTAGLANDIN E2
Several lines of evidence suggest that the deregulation of the
cyclooxygenase (COX)-2/PGE2 pathway is a key factor in tumor
evasion of the immune response (77). COX enzymes catalyze
the formation of prostaglandins from arachidonic acid following
sequential oxidation. Interestingly, COX-2 can be overexpressed in
both adenoma and carcinoma cells under hypoxia via a mechanism
dependent on HIF-1α. This upregulation is associated with PGE2
overproduction and secretion in the microenvironment (78). Early
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studies showed that PGE2 suppresses the cytolytic activity of NK
cells (79, 80) by a mechanism related to the inhibition of IFN-
γ production (81, 82). Recently, Pietra et al. have shown that
melanoma cells affect the function of NK cells by downregulating
the surface expression of activating receptors, including NKp30,
NKp44, and NKG2D. This impairment appears to be related, at
least in part, to PGE2 production by melanoma cells as PGE2-
specific inhibitor-restored NK cell functions (47). In addition to
its direct effect on NK cells, more recent data reported that PGE2
can indirectly affect the NK cell function by promoting the estab-
lishment of an immunosuppressive microenvironment through
the induction of Treg cells (83), macrophages (84), and MDSCs
(27, 85) development.
GALECTINS
Galectins (Gal) are proteins belonging to the lectins family that
participate in the delivery of signals after binding to glycopro-
teins and glycolipids on the cell surface of target cells. Using a
proteomic approach, Le et al. have identified Gal-1 as a novel
hypoxia-regulated protein (86). They proposed that tumor aggres-
siveness of HNSCC is dependent on hypoxia-mediated production
and the secretion of Gal-1, which in turn negatively regulates
the anti-tumor immune response. Additional studies have sup-
ported the contribution of Gal-1 in creating an immunosuppres-
sive microenvironment at the sites of tumor growth by several
mechanisms (87). Thus, it has been reported that recombinant
Gal-1 is able to promote the differentiation of CD4+CD25+
Treg cells in vitro (88). Recently, Dalotto-Moreno et al. showed
that tumor-derived Gal-1 increases the abundance and/or the
expansion of peripheral Treg cells in vivo and modulates their
suppressive capacity. Conversely, attenuation of Gal-1 reduces the
frequency of Treg cells within tumors, lymph nodes, and spleen
and removes the immunosuppressive function of Treg cells (89).
More recently, Gal-3, another member of the galectin family regu-
lated by HIF-1α (90), was reported to exert an immunosuppressive
function in the TME. Tsuboi et al. provided evidence that cell
surface Gal-3 on bladder tumor cells modulates MICA-NKG2D
interactions by binding MICA through poly-N -acetyllactosamine,
thereby severely impairing the NK cell activation and degranula-
tion (91). The effect of Gal-9 is still debated as it may regulate both
positively and negatively the NK cell response depending on the
activation threshold and the expression of its receptor. Gleason
et al. have shown that Gal-9 binding to the immune receptor T cell
Ig and mucin-containing domain-3 (Tim-3) enhances the produc-
tion of IFN-γ by NK cells (92). Conversely, higher doses of Gal-9
impair the cytotoxic function of NK cells in a Tim-3 independent
manner (93).
REGULATION OF NK CELL-MEDIATED KILLING BY
AUTOPHAGY
It has become increasingly clear that tumor cells activate key
biochemical and cellular pathways under hypoxic stress that
are important for tumor progression, survival, and metasta-
sis. Several recent reports highlight autophagy as a critical
process that modulates the anti-tumor immune response. Briefly,
autophagy is a catabolic process in which a cell self-digests its
own components. Autophagy can be activated in response to
multiple stressors including hypoxia, nutrient starvation, growth
factor withdrawal, and endoplasmic reticulum stress. Under stress-
ful stimuli, autophagy activation serves as an adaptive response
to provide nutrients and prevents accumulation of altered cell
components (94).
To adapt to hypoxia, cells activate autophagy through both
HIF-1α dependent and independent pathways, depending on the
sensor activated (95). The role of autophagy in cancer immunity
seems to be complex as hypoxia-induced autophagy occurs in tar-
get cells and in tumor-infiltrating immune cells. Although the role
of autophagy induction in target cells is well documented, rela-
tively little attention has been given to its role in immune cells.
Therefore, understanding how autophagy modulates the tumor
immune response represents a major challenge in the field of
tumor immunotherapy. Recently, it has been reported that NK
cells not only provide lytic signals to their target cancer cells,
but also promote autophagy in the remaining un-killed target
cells. Moreover, the NK-mediated autophagy induction in target
cells was enhanced by provision of IL-2 and cell-cell interactions
between NK cells and tumor cells. This study highlights autophagy
induction in target cells as a cell mechanism of resistance to NK-
mediated killing (96). More recently, we showed in vitro and in vivo
that targeting autophagy under hypoxia restores NK-mediated
lysis in breast cancer cells. In addition, we provided mechanis-
tic evidence that the activation of autophagy under hypoxia led
to the degradation of NK-derived granzyme B, making hypoxic
tumor cells less sensitive to NK-mediated killing (Figure 4) (97).
TUMOR-DERIVED EXTRACELLULAR VESICLES INFLUENCE NK
CELL ACTIVITY
Recent advances have led to the identification of an additional
mechanism used by tumor cells to escape NK cell recognition and
impair the NK-mediated immune response (98). Indeed, tumor
cells release vesicle-bound molecules (cytokines, NKG2D ligands,
and miRNAs) targeting and inhibiting NK cell functions (99).
Exosomes are 50–150 nm membrane vesicles derived from the
multi-vesicular bodies that are secreted by all cell types [reviewed
in Ref. (100)]. As a consequence, exosomes are found in many
biological fluids such as urine, plasma, and saliva. As their content
reflects the cells from which they are derived, exosomes represent,
therefore, attractive biomarkers (101). Exosomes and other types
of extracellular vesicles are well-known mediators of intercellu-
lar communication and play a crucial role in the development of
aggressive and metastatic tumors (102, 103).
CANCER CELL-DERIVED EXOSOMES
The production of NKG2D ligand-bearing exosomes has been
proposed as a mechanism for tumor cell escape from immune
recognition (99, 104, 105). Indeed, it has been demonstrated that,
in contrast to ULPB2, released ULBP3 is included into exosomes.
Remarkably, ULBP3-containing exosomes have been shown to
be more potent downregulators of the NKG2D receptor than
the soluble form of ULBP2 proteins released by the metallo-
proteinases ADAM10 and 17. Pre-incubation of NK cells with
ULBP3-containing exosomes induced a dramatic reduction of
NKG2D-mediated lysis of MICA-expressing cells (106). Tumor-
derived exosomes (TDEs) are rapidly taken up by NK cells and
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FIGURE 4 | Hypoxic stress activates autophagy in tumor cells as an
intrinsic resistance mechanism to NK-mediated killing. In our model,
the cytolytic effectors perforin and granzyme B enter the target cells by
endocytosis and then are found in enlarged endosomes called
“gigantosomes.” In hypoxic cells, the activation of autophagy leads to the
formation of autophagosomes that fuse with “gigantosomes” to form
amphisomes. The fusion between amphisomes and lysosomes selectively
degrades granzyme B in this compartment, making hypoxic tumor cells less
sensitive to NK-mediated lysis.
remain stable for 48 h (104, 107). The transfer of TDE-bearing,
membrane-anchored TGF-β, MICA, and MICB leads to the down-
regulation of NKG2D expression at the surface of NK cells and
impairs their cytotoxic functions (Figure 5) (99, 108). However,
TDEs can only weakly impair the NK cell proliferation compared
with their strong negative effect on the proliferation of CD8+ T
cells (109). Nevertheless, numerous studies highlighted TGF-β as a
major immunosuppressive molecule for NK cells (108, 110, 111).
Indeed, an elevated plasma level of TGF-β was detected in lung or
colorectal cancer patients compared with healthy volunteers. This
increase inversely correlated with NKG2D surface expression on
NK cells in these patients (110). Recently, TGF-β was shown to
block NK cell activation by repressing gene expression and antag-
onizing IL-15-induced proliferation (111). A striking observation
was also done by Clayton et al. who identified exosomal TGF-β1
FIGURE 5 | Impairment of NK cell function by tumor-derived
exosomes. Tumor cells secrete extracellular vesicles called exosomes.
Tumor-derived exosomes contain numerous factors able to modulate the
function of NK cells such as MICA/B, ULBP3, TGF-β, PI-9, and different
microRNAs. Exosome-derived MICA/B, ULBP3, TGF-β, and miR-1245 can
decrease NKG2D on the surface of NK cells, while PI-9 degrades granzyme
B. Tumor-derived exosomes can also decrease the level of perforin in NK
cells by a still-unknown mechanism.
as a more potent contributor to antiproliferative effects than the
soluble form (109).
Several cancer models have generated evidence supporting the
important roles of TDEs. Indeed, mammary carcinoma exosomes
promote tumor growth by suppressing NK cell function in mice
(104). A decrease in splenic NK cell cytotoxicity was observed after
in vivo injection of TDEs. Moreover, a reduction in the number
and the percentage of NK cells was observed in the lungs 3 days
after exosome injection, without a reduction in the viability of
the NK cells. Interestingly, TDEs also reduced the expression of
the NK pore-forming and cytolytic protein perforin (Figure 5)
(104, 111), whereas the level of granzyme B was unaffected (104).
A decrease in NK cell proliferation in response to IL-2 was also
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observed after treatment with exosomes derived from different
tumor cell types (breast and melanoma) due to the inhibition of
the JAK-STAT signaling. However,TDEs did not affect DC matura-
tion but hampered their ability to stimulate the immune response
(104). The granzyme B-inhibitory serpin proteinase inhibitor-9
(PI-9) has also been identified inside exosomes (112) and could
also play an important role in the resistance of tumor cells to NK
cells (Figure 5). Taken together, these data highlight the crucial
role that TDEs may have on the tumor immunosurveillance by
affecting the NK cell receptors, proliferation, and release of cyto-
toxic molecules, thus impairing an effective anti-cancer immune
response.
Numerous studies have provided evidence that hypoxic stress
may influence the composition of TDEs. Indeed, to substitute
oxygen deprivation and a lack of nutrients, tumor cells induce
the expression of angiogenic factors to overcome hypoxic stress
through the formation of new blood vessels from existing vascu-
lature. In addition to secreted VEGF, several chemokines (G-CSF,
GM-CSF, CXCL16, and SDF-1) and exosomes were shown to be
important mediators for tumor cells to overcome hypoxic stress
(102). In this context, it has been reported that tumor cells under
hypoxic stress secrete numerous proteins sequestered in exosomes
involved in cell–cell communication, cell growth, and malignant
transformation. Other studies have focused on how hypoxia-
induced membrane vesicles stimulate angiogenesis in malignant
and angiogenic brain tumor glioblastoma multiforme (GBM).
Indeed, hypoxic cancer cells release exosomes containing tissue
factor (TF) acting on surrounding endothelial cells in a paracrine
manner, leading to the activation of a protease-activated receptor
2 (PAR2)-ERK signaling pathway (113). PAR2 has been recently
identified as a regulator of the innate immune response and a
mediator of cell proliferation and migration. Also called throm-
boplastin, TF forms a complex with the tissue protease factor VIIa
and is necessary for the initiation of thrombin formation. Because
hypoxic tumors are often characterized by endothelial cell hyper-
plasia and hypercoagulation, the combined presence of newly gen-
erated fibrin and activated platelets has been shown to protect the
tumor from NK cells and immune surveillance (114). Further find-
ings obtained with GBM cells indicates that hypoxic conditions
stimulated tumor cells to generate exosomes containing proteins
that reflect the hypoxic status of the tumor cells. These findings
support the hypothesis that the microenvironment significantly
impacts the TDE composition. The enrichment in exosomes of
specific hypoxia-related RNAs and proteins (cytokines,growth fac-
tors, and MMP) could indeed be associated with a poor patient
prognosis. In addition, hypoxic TDEs mediated a strong paracrine
stimulation of angiogenesis and activation of cancer cells, leading
to an acceleration of tumor growth in a mouse xenograft model
(115). TDEs systematically contain several members of the ADAM
family, mostly ADAM10 (107), which is able to shed NKG2D lig-
ands from the cell membrane (116). Finally, besides stimulating
the production of exosomes with a specific content, hypoxia has
also been shown to enhance exosome release by cancer cells (92).
Besides solid tumors, circulating tumor cells, such as leukemic
cells, escape NK surveillance at a systematic level in blood. It is
important to note that leukemic cells are constantly recirculat-
ing in the bone marrow, where the environment is maintained in
constant hypoxia (117). Recent studies have shed light on mecha-
nisms of tumor cell escape from NK-mediated killing that could be
used as new therapeutic approaches. These mechanisms include
the shedding of soluble (BAG6, and MICA) or exosome-derived
inhibitory molecules (TGF-β) in various malignancies such as
acute myeloid leukemia (118), chronic lymphocytic leukemia
(119), and Hodgkin’s lymphoma (119).
SECRETED microRNAs
As described above, under hypoxic conditions, most cell types
undergo important metabolic changes orchestrated by members
of the HIF transcription factor family. It is well documented
that HIF-1α is a potent inducer of miR-210 (120), which has
been described to be released by tumor cells (121, 122). It has
been shown that miR-210 released by leukemic and metastatic
cancer cells may be transported by exosomes and enter endothe-
lial cells (121, 122). In the recipient cells, miR-210 is able to
induce angiogenesis and promote tumor growth. These data high-
light the role of exosomal miR-210 in the shaping of the TME
and the potential action on various cell types present at the
tumor site. Although the data available are limited, we believe
that exogenous miRNAs can impair the anti-tumor function of
immune cells (Figure 5). In line with this concept, it has been
shown that the TGF-β1-induced miR-1245 downregulated the
NKG2D receptor on NK cells and impaired NKG2D-mediated
functions (123). The influence of exogenous miRNAs on NK
cells is currently unknown but understanding this new regula-
tory mechanism may help to improve the outcome of NK-based
immunotherapy.
CONCLUSION
Recent developments in cancer immunotherapies have now begun
to explore the use of NK cells (15, 124). Particularly, strategies
designed to improve NK-mediated killing using tumor-specific
mAbs have shown promising results in preclinical and some clini-
cal settings (125). This review has summarized the different mech-
anisms involved in the impairment of NK-mediated tumor killing
and highlighted that the majority of these mechanisms likely
evolve within the TME. In this regard, it should be emphasized that
the composition and characteristics of the TME are important in
determining the anti-tumor immune response. For example, dif-
ferent subsets of the immune system, including NK cells, DCs, and
effector T cells, are capable of driving potent anti-tumor responses.
However, the ability of tumor cells to exploit other cells present in
the TME is now widely regarded as a critical factor that switches
the immune response from a tumor-destructive profile to a tumor-
promoting profile. Such a microenvironment may also favor the
development of immunosuppressive populations of immune cells,
such as MDSCs, TAMs, and Treg cells.
Despite recent advances in cancer immunotherapy, the ther-
apeutic outcome was often disappointing in many clinical pro-
tocols. Given the important immunomodulatory effects of the
TME, it stands to reason that it may represent a therapeutic tar-
get that can be manipulated to improve the anti-tumor immune
response. Thus, the first clinical interventions that aim to target the
microenvironment to enhance tumor immunity are under active
evaluation.
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Overall, investigations oriented toward the identification of
novel therapeutic strategies, aiming to improve the anti-tumor
immunotherapy, should pay closer attention to the TME to awake
or reawake immune cells and/or to redirect such a microenviron-
ment from a pro-tumor to an anti-tumor state. Given its central
role in tumor progression and resistance to therapy, the hypoxic
TME should be considered as a new critical therapeutic target in
oncology. We believe that a better characterization of the TME can
provide important prognostic and predictive values independent
of the tumor phenotype.
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